Physician profile
William M Rafelson
NPI 1992142046
$6,938.48
in general payments reported to CMS, 2019-2025
36 companies · $860 in 2025
The $860 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $380 · 2024: $5,698 · 2025: $860.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,316 · Honoraria: $1,978 · Consulting Fee: $1,435 · Travel and Lodging: $206 · Education: $3.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,315.74 |
| Honoraria | $1,977.50 |
| Consulting Fee | $1,435.00 |
| Travel and Lodging | $206.46 |
| Education | $3.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $2,260.51 | 2024-2025 | Cabometyx |
| Aveo Pharmaceuticals, INC. | $910.00 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $630.40 | 2023-2025 | Imfinzi, Lynparza, Enhertu |
| E.R. Squibb & Sons, L.L.C. | $592.53 | 2023-2025 | Opdivo, Opdualag |
| Pfizer INC. | $310.22 | 2023-2025 | |
| Daiichi Sankyo INC. | $307.17 | 2023-2025 | Enhertu, Vanflyta, Injectafer |
| Merck Sharp & Dohme LLC | $298.72 | 2023-2025 | Keytruda, Lynparza, Reblozyl |
| Novartis Pharmaceuticals Corporation | $258.60 | 2024-2025 | |
| Ferring Pharmaceuticals INC. | $168.81 | 2024 | Adstiladrin, Firmagon |
| Medtronic, INC. | $136.04 | 2024 | Interstim |
| Janssen Biotech, INC. | $129.99 | 2023-2025 | Tecvayli, Talvey, Darzalex |
| Sun Pharmaceutical Industries INC. | $116.82 | 2023-2025 | Yonsa, Odomzo |
| Astellas Pharma US INC | $99.79 | 2024-2025 | Padcev |
| Mirati Therapeutics, INC. | $74.12 | 2024 | Krazati |
| Kerecis Limited | $59.35 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Array Biopharma INC | $58.91 | 2024-2025 | Mektovi, Braftovi, Lorbrena |
| Genentech USA, INC. | $58.30 | 2023-2024 | Tecentriq, Rozlytrek, Alecensa |
| Celgene Corporation | $54.54 | 2025 | Reblozyl |
| Emd Serono, INC. | $47.35 | 2024 | |
| Genmab U.S., INC. | $34.45 | 2024-2025 | Epkinly |
| Alexion Pharmaceuticals, INC. | $33.77 | 2024 | Ultomiris |
| Pharmaessentia USA Corporation | $32.53 | 2023-2024 | Besremi |
| Foundation Medicine, INC. | $28.33 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.26 | 2024 | Vpriv |
| Immunogen, INC. | $21.13 | 2024 | Elahere |
| Myriad Genetic Laboratories, INC. | $20.62 | 2024 | Myrisk |
| Tempus Ai, INC | $20.15 | 2024 | Xt Cdx |
| Bayer Healthcare Pharmaceuticals INC. | $18.66 | 2024 | |
| Lilly USA, LLC | $18.45 | 2024 | Retevmo, Jaypirca, Verzenio |
| Blueprint Medicines Corporation | $17.35 | 2023 | Ayvakit |
| Tersera Therapeutics LLC | $17.00 | 2023 | Zoladex |
| Cumberland Pharmaceuticals, INC. | $16.59 | 2024 | Sancuso |
| Pharmacosmos Therapeutics INC. | $16.11 | 2024 | Monoferric |
| Galvanize Therapeutics, INC | $15.76 | 2024 | Aliya System |
| Genzyme Corporation | $15.17 | 2024 | |
| Azurity Pharmaceuticals, INC. | $13.98 | 2024 | Vivimusta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Rafelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.